Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Hims and Hers Health Inc (HIMS) Price & Performance

Invesco DB Commodity Index Tracking FundTrade
Hims and Hers Health IncTrade

Price performance (Past 24H)

Key statistics

Invesco DB Commodity Index Tracking Fund vs Hims and Hers Health Inc — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $28.98, while Hims and Hers Health Inc trades at $35.38 (market cap $8.14B). The key difference: Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals.

DBCHIMS
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$31.69$66.18
52-Week Low
$21.62$14.52
Market Cap
$8.14B
Enterprise Value
$8.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco DB Commodity Index Tracking Fund

DBC, the Invesco DB Commodity Index Tracking ETF, trades at $28.33, up 2.94% today, with a bullish technical signal from moving averages and oscillators. Recent news highlights its role as an inflation hedge, with a 52-week high noted in April 2026. The ETF provides diversified commodity exposure, benefiting from oil supply shocks and safe-haven demand, though key financial ratios like P/E and P/S are not applicable for this fund structure.

Outlook remains positive due to strong momentum and inflation hedging appeal, but risks include commodity price volatility and geopolitical factors. Analyst sentiment is supportive, with the ETF favored in balanced portfolios for moderate-risk investors seeking commodity diversification amid market uncertainty.

Hims and Hers Health Inc

Hims & Hers Health trades at $34.38, showing no change in the last session. The stock exhibits a bullish technical setup with moving averages supporting upward momentum, while oscillators remain neutral. Recent earnings have been mixed, with Q1 2026 missing expectations, but revenue growth remains positive. Analyst sentiment is divided with a 35% buy rating, and the consensus price target is $33.57. News highlights include expansion in weight-loss treatments and a new JPMorgan receivables facility.

The outlook for HIMS is cautiously optimistic, driven by growth in telehealth and weight-loss segments, but high valuation multiples and recent net income declines pose risks. Investment opportunity lies in market expansion and subscriber growth, while execution risks and competitive pressures require monitoring.

Returns comparison

Trailing returns across standard periods

About Invesco DB Commodity Index Tracking Fund

DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.

Read more on DBC

About Hims and Hers Health Inc

Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.

Read more on HIMS